John M. Buatti
This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.
This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time. WHO grade IV gliomas are the most common primary brain tumors. Despite aggressive standard of care treatment, overall survival remains low. Early identification of whether the glioma comes back after a period of improvement (recurrence) remains an important part of treatment management. Early identification of recurrence can be complicated as treatment effects…
Inclusion Criteria: * Age \> 21 years * New pathologically confirmed diagnosis of WHO grade IV malignant glioma * KPS \> 60 * Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol Exclusion Criteria: * History of previous malignancy other than non-melanoma skin cancer in the previous 5 years * History of iron metabolic disorder such as hemochromatosis * Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices
Undergo T2\* MRI
Undergo blood sample collection
Undergo standard MRI
Arctuva estimate
Verify or correct the compensation shown for this listing.